回生口服液联合奥希替尼治疗晚期非小细胞肺癌患者的效果

doi:10.3969/j.issn.1671-7171.2026.09.015

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1257 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To evaluate the efficacy of Huisheng Oral Liquid combined with osimertinib in the treatment of patients with advanced non-small cell lung cancer (NSCLC). 【Methods】 A total of 72 patients with advanced NSCLC admitted from May 2020 to August 2022 were randomly divided into a control group and an observation group, with 36 cases in each group. The control group received oral osimertinib alone, while the observation group received Huisheng Oral Liquid in addition to osimertinib. Clinical efficacy, tumor marker levels [cyto-keratin 19 fragment antigen 21-1(CYFRA21-1), neuron-specific enolase (NSE), and squamous cell carcinoma antigen (SCCAg)], immune function indices (CD4⁺ T cells, CD8⁺ T cells, CD3⁺ T cells), and adverse drug reactions were compared between the two groups before and after treatment. Patients were followed up for 3 years, and overall survival (OS) and progression-free survival (PFS) were compared between the two groups. 【Results】 After treatment, the objective response rate and overall response rate in the observation group were significantly higher than those in the control group (P<0.05). The levels of CYFRA21-1, NSE, and SCCAg in the observation group were significantly lower than those in the control group (P<0.05). The observation group showed higher CD4⁺ and CD3⁺ levels and lower CD8⁺ levels compared to the control group (P<0.05). The overall incidence of adverse reactions was lower in the observation group than in the control group (P<0.05). The median OS and PFS were significantly longer in the observation group than in the control group (P<0.05). 【Conclusion】 Huisheng Oral Liquid combined with osimertinib can significantly improve the efficacy in patients with advanced NSCLC, reduce tumor marker levels, enhance immune function, alleviate side effects, and improve survival outcomes.

Key words： Non Small Cell Lung Cancer Huisheng Oral Liquid Osimertinib Treatment Outcome

Received: 31 October 2025

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Qingpo

Cite this article:

CHEN Qingpo. Efficacy of Huisheng Oral Liquid Combined with Osimertinib in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(9): 1463-1465.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.09.015 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I9/1463

[1] 李萱,潘华,张晓鹏,等.达克替尼联合西妥昔单抗治疗晚期非小细胞肺癌的临床疗效及生存情况分析[J].医学临床研究,2024,41(3):420-423.
[2] LI X F, ZHAI Z Q, ZHU Y C, et al. Comparison of Gefitinib in the treatment of patients with non-small cell lung cancer and clinical effects of Osimertinib and EGFR Gene mutation[J]. Pak J Med Sci, 2022, 38(6): 1589-1594.
[3] 贾克刚,冯刚.回生口服液上市后用药安全性系统评价[J].中药药理与临床,2021,37(5):155-164.
[4] 中华医学会,中华医学会肿瘤学分会,中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2018版)[J]. 中华肿瘤杂志,2018,40(12):935-964.
[5] Schwartz L H, Litière S, DE Vries E, et al. RECIST 1.1-Update and clarification: from the RECIST committee[J]. Eur J Cancer, 2016, 62(2): 132-137.
[6] 孙晓庆,宗明园,傅露. 系统免疫炎症指数对非小细胞肺癌患者预后的预测作用[J]. 华南国防医学杂志,2021,35(12):866-870.
[7] 籍强,吕骏卿,赵鑫,等. 晚期NSCLC组织巨噬细胞表面Tim-3表达与临床特征和预后的关系[J]. 中南医学科学杂志,2021,49(6):668-671.
[8] 刘超星,严雪冰,杨梦雪,等. 非小细胞肺癌免疫治疗的临床影响因素[J]. 国际肿瘤学杂志,2021,48(12):751-754.
[9] 朱文玲,施如意,徐静静,等.个案管理策略对老年非小细胞肺癌免疫治疗患者的心理状态及生存质量的影响[J].医学临床研究,2025,42(1):128-131.
[10] 戴冰,李昊,占美,等. 紫杉醇白蛋白结合型联合卡铂一线治疗晚期非小细胞肺癌合并肾功能损伤患者的成本效果分析[J]. 中国医院药学杂志,2020,40(24):2526-2530.
[11] 李慧,李伟,王淑英. 吉非替尼联合化疗对晚期非小细胞肺癌的疗效及安全性分析[J]. 国际检验医学杂志,2020,41(24):2957-2961.
[12] 孙秀凤,周芬,吴婷. 扶正散结合剂联合厄洛替尼在晚期非小细胞肺癌患者中的临床效果及对肿瘤标志物的影响研究[J]. 世界中西医结合杂志,2021,16(1):104-107.
[13] 余嗣崇,王荣荣,许新举,等. 回生口服液、重组人血管内皮抑制素联合GP方案对晚期非小细胞肺癌患者的临床疗效[J]. 中成药,2021,43(7):1971-1973.
[14] 张金华,田园,杨晓萍,等. 回生口服液对非小细胞肺癌患者凝血功能、疗效及安全性影响的系统评价[J]. 中国医院用药评价与分析,2022,22(10):1237-1243.